[*] = Certain confidential information contained in this document, marked by
brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

 

                                                                                                                                                            Exhibit
10.1

 

 

[g201511120637509844167.jpg]

 

Change Order Form

 

 

Change Order No.: 3

 

Change Order Submission Date:10 July 2015

 

Sponsor: ARCA biopharma Inc. (“Sponsor”)

 

Study Drug/Protocol No.: BUC-CLIN-303

 

Study Title:   GENETIC-AF (“Study”)

 

EPM#: 5969

 

SPS#: 200267

 

Sponsor Contact:  

[*]

 

DCRI Contacts:

 

Project Leader:

[*]

 

Business Development:

[*]

 

 

Sponsor and Duke University (“Duke” or “DCRI”) entered in a Clinical Research
Agreement (the “Agreement”), effective 05 November 2013, to conduct the
above-referenced Project. Change Order No. 1 was executed November 2014 and
Change Order No. 2 was executed 10 March 2015. This Change Order No. 3 serves as
an amendment to the Agreement and provides details related to scope changes and
associated budget adjustments.  

 

Description of Scope Changes:  The budget for this Change Order No. 3 is
detailed in Attachment 1:  “DCRI Detailed Fees and Pass-through Cost Estimate,”
and an explanation of the change is referenced in the column called
“Justification for Revised Scope”.  Unless otherwise noted, the unit costs
remain the same.

 

--------------------------------------------------------------------------------

Study Timeline

There are no changes to the timeline.

 

Description of Budget Change Summary:

 

Type

Contract Value through
Change Order No. 2

Change Order
No. 3 Value

Revised Total

DCRI Direct Fees

[*]

[*]

[*]

Pass-through Costs

[*]

[*]

[*]

Total

[*]

[*]

[*]

 

See attached budget file.

The DCRI will invoice completed units on a monthly basis.  All payments remain
as agreed upon as in the Agreement unless otherwise stated.

Approval Signature:

 

Sponsor:

 

 

By:  /s/ Brian L. Selby

 

Title: V.P. Finance & Chief Accounting Officer

 

Date: August 10, 2015

Duke University:

 

 

By:  /s/ David S. Hill

 

Title: Assistant Director, Finance – DCRI

 

Date: August 27, 2015

 

 

 

 

 

 

 

 

 

[*] = Certain confidential information contained in this document, marked by
brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended

--------------------------------------------------------------------------------

Attachment 1

 

DCRI Detailed Fees and Pass-through Cost Estimate

 

 

 

[* 4 pages of text omitted]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] = Certain confidential information contained in this document, marked by
brackets, is filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended